Sareum Holdings PLC (GB:SAR)
LSE:SAR
SAR Stock Chart & Stats
15.00 p
0.10 p(0.44%)
At close: 4:00 PM EST
15.00 p
0.10 p(0.44%)
Day’s Range― - ―
52-Week Range9.50 p - 29.00 p
Previous CloseN/A
Volume41.80K
Average Volume (3M)619.72K
Market Cap
£21.40M
Enterprise Value18.91M
Total Cash (Recent Filing)£2.49M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.42
Next Earnings
Oct 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding138,065,170
10 Day Avg. Volume1,134,615
30 Day Avg. Volume619,716
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)8.68
Price to Sales (P/S)0.00
P/FCF Ratio-7.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£43.15M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetNo reported debt removes fixed interest obligations and lowers insolvency risk, giving Sareum flexibility to structure financing, extend runway or prioritise R&D spend. Over the next 2–6 months this durable financial buffer supports partner negotiations and reduces refinancing pressure.
Licensing / Partnership Monetisation ModelAn asset-light model based on licensing, milestones and collaboration fees enables scalable upside without product-commercialisation burden. Structurally this can generate lumpy but non-dilutive milestone/royalty streams as pipeline assets are partnered, preserving focus on discovery.
Specialised Kinase-inhibitor PlatformTechnical focus on kinase inhibition provides a clear scientific niche and transferable IP, supporting repeated discovery efforts and partner interest. A durable platform expertise increases likelihood of creating partnerable candidates and sustained R&D productivity over the medium term.
Bears Say
Pre-revenue And Persistent LossesSareum remains pre-revenue with recurring operating and net losses, meaning the business cannot self-fund operations. Over 2–6 months this structural lack of commercial income forces reliance on external financing, increasing dilution and execution risk for development programmes.
Significant Cash BurnConsistent negative operating and free cash flow, despite recent narrowing, implies ongoing funding needs. This persistent burn requires frequent capital raises or partner deals, limiting strategic optionality and potentially delaying programmes if financing windows tighten.
Small, Volatile Equity BaseA small and volatile equity base coupled with negative ROE reduces the firm’s ability to absorb development setbacks and increases sensitivity to funding cycles. Structurally, this heightens refinancing risk and can force suboptimal deal terms or dilution when capital is required.
Sareum Holdings News
SAR FAQ
What was Sareum Holdings PLC’s price range in the past 12 months?
Sareum Holdings PLC lowest share price was 9.50 p and its highest was 29.00 p in the past 12 months.
What is Sareum Holdings PLC’s market cap?
Sareum Holdings PLC’s market cap is £21.40M.
When is Sareum Holdings PLC’s upcoming earnings report date?
Sareum Holdings PLC’s upcoming earnings report date is Oct 26, 2026 which is in 204 days.
How were Sareum Holdings PLC’s earnings last quarter?
Sareum Holdings PLC released its earnings results on Mar 12, 2026. The company reported -0.012 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.012 p.
Is Sareum Holdings PLC overvalued?
According to Wall Street analysts Sareum Holdings PLC’s price is currently Overvalued.
Does Sareum Holdings PLC pay dividends?
Sareum Holdings PLC does not currently pay dividends.
What is Sareum Holdings PLC’s EPS estimate?
Sareum Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sareum Holdings PLC have?
Sareum Holdings PLC has 138,065,170 shares outstanding.
What happened to Sareum Holdings PLC’s price movement after its last earnings report?
Sareum Holdings PLC reported an EPS of -0.012 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.143%.
Which hedge fund is a major shareholder of Sareum Holdings PLC?
Currently, no hedge funds are holding shares in GB:SAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sareum Holdings PLC
Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.
Technical Analysis
ImmuPharma
―
Fusion Antibodies Plc
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---